PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 15, 2014--
Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial
results for the company’s third quarter ended September 30, 2014, will
be released before the market opens on Thursday, October 30, 2014. The
Pacira management team will host a conference call to discuss the
company’s financial results and recent and upcoming developments on
Thursday, October 30, 2014, at 9 a.m. ET. The call can be accessed by
dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international)
fifteen minutes prior to the start of the call and providing the
Conference ID 2794612.
A replay of the call will be available approximately two hours after the
completion of the call and can be accessed by dialing 1-855-859-2056
(domestic) or 1-404-537-3406 (international) and providing the
Conference ID 2794612. The replay of the call will be available for two
weeks from the date of the live call.
The live, listen-only webcast of the conference call can also be
accessed by visiting the “Investors & Media” section of the company’s
website at investor.pacira.com.
A replay of the webcast will be archived on the Pacira website for two
weeks following the call.
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is a specialty
pharmaceutical company focused on the clinical and commercial
development of new products that meet the needs of acute care
practitioners and their patients. The company’s current emphasis is the
development of non-opioid products for postsurgical pain control, and
its lead product, EXPAREL® (bupivacaine liposome injectable
suspension), was commercially launched in the United States in April
2012. EXPAREL and two other products have utilized the Pacira
proprietary product delivery technology DepoFoam®, a unique
platform that encapsulates drugs without altering their molecular
structure and then releases them over a desired period of time.
Additional information about Pacira is available at www.pacira.com.
Source: Pacira Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc.
Jessica Cho, 973-254-3574